CA2685134A1 - Utilisation de derives de furopyrimidine a substitution cyclique dans le traitement de l'hypertonie arterielle pulmonaire - Google Patents

Utilisation de derives de furopyrimidine a substitution cyclique dans le traitement de l'hypertonie arterielle pulmonaire Download PDF

Info

Publication number
CA2685134A1
CA2685134A1 CA002685134A CA2685134A CA2685134A1 CA 2685134 A1 CA2685134 A1 CA 2685134A1 CA 002685134 A CA002685134 A CA 002685134A CA 2685134 A CA2685134 A CA 2685134A CA 2685134 A1 CA2685134 A1 CA 2685134A1
Authority
CA
Canada
Prior art keywords
group
mmol
alkyl
mixture
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002685134A
Other languages
English (en)
Inventor
Thomas Lampe
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Mario Jeske
Joachim Schuhmacher
Friederike Stoll
Metin Akbaba
Andreas Knorr
Johannes-Peter Stasch
Lars Baerfacker
Alexander Hillisch
Gunter Karig
Mark Meininghaus
Karl-Heinz Schlemmer
Rudolf Schohe-Loop
Martina Delbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Thomas Lampe
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Mario Jeske
Joachim Schuhmacher
Friederike Stoll
Metin Akbaba
Andreas Knorr
Johannes-Peter Stasch
Lars Baerfacker
Alexander Hillisch
Gunter Karig
Mark Meininghaus
Karl-Heinz Schlemmer
Rudolf Schohe-Loop
Martina Delbeck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft, Thomas Lampe, Eva-Maria Becker, Raimund Kast, Hartmut Beck, Mario Jeske, Joachim Schuhmacher, Friederike Stoll, Metin Akbaba, Andreas Knorr, Johannes-Peter Stasch, Lars Baerfacker, Alexander Hillisch, Gunter Karig, Mark Meininghaus, Karl-Heinz Schlemmer, Rudolf Schohe-Loop, Martina Delbeck filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of CA2685134A1 publication Critical patent/CA2685134A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
CA002685134A 2007-04-26 2008-04-16 Utilisation de derives de furopyrimidine a substitution cyclique dans le traitement de l'hypertonie arterielle pulmonaire Abandoned CA2685134A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007019690A DE102007019690A1 (de) 2007-04-26 2007-04-26 Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019690.5 2007-04-26
PCT/EP2008/003008 WO2008131859A2 (fr) 2007-04-26 2008-04-16 Utilisation de dérivés de furopyrimidine à substitution cyclique dans le traitement de l'hypertonie artérielle pulmonaire

Publications (1)

Publication Number Publication Date
CA2685134A1 true CA2685134A1 (fr) 2008-11-06

Family

ID=39777458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002685134A Abandoned CA2685134A1 (fr) 2007-04-26 2008-04-16 Utilisation de derives de furopyrimidine a substitution cyclique dans le traitement de l'hypertonie arterielle pulmonaire

Country Status (3)

Country Link
CA (1) CA2685134A1 (fr)
DE (1) DE102007019690A1 (fr)
WO (1) WO2008131859A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092528A1 (fr) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
EP1018514B1 (fr) 1998-07-22 2004-05-12 Daiichi Suntory Pharma Co., Ltd. INHIBITEURS DE NF-$g(k)B CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
EP1181296A1 (fr) 1999-06-03 2002-02-27 Abbott Laboratories Composes anti-inflammatoires inhibant l'adhesion cellulaire
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
CA2350992C (fr) 1999-09-17 2009-06-23 Suntory Limited Moyens de prevention ou therapeutique contre la myocardite, la cardiomyopathie dilatee et l'insuffisance cardiaque contenant des inhibiteurs nf-kb en tant qu'ingredient actif
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
CA2449188A1 (fr) 2001-05-14 2002-11-21 Novartis Ag Oxazolopyrimidines et furopyrimidines et utilisation dans des agents pharmaceutiques contre les tumeurs
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
WO2003053930A1 (fr) 2001-12-20 2003-07-03 Bayer Healthcare Ag Derives de 1,4-dihydro-1,4-diphenylpyridine
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003293356A1 (en) 2002-08-27 2004-03-19 Bayer Healthcare Ag Dihydropyridinone derivatives as hne inhibitors
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
AU2003255492A1 (en) 2002-09-10 2004-04-30 Bayer Healthcare Ag Heterocyclic derivatives
US7687510B2 (en) 2002-09-10 2010-03-30 Bayer Healthcare Ag Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
JP5134248B2 (ja) 2004-02-19 2013-01-30 バイエル・ファルマ・アクチェンゲゼルシャフト ジヒドロピリジノン誘導体
CA2557271C (fr) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones et leur utilisation en tant qu'inhibiteurs de l'elastase du neutrophile humaine
WO2005082863A2 (fr) 2004-02-26 2005-09-09 Bayer Healthcare Ag Derives heterocycliques
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
WO2005121149A1 (fr) 2004-06-10 2005-12-22 Xention Discovery Limited Composes de furanopyrimidine efficaces comme inhibiteurs des canaux potassiques
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
DE102005061171A1 (de) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung

Also Published As

Publication number Publication date
WO2008131859A3 (fr) 2009-07-16
WO2008131859A2 (fr) 2008-11-06
DE102007019690A1 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
IL271117A (en) Imidazopyrimidines are diazabicyclic metastases and their use in the treatment of respiratory disorders
TW201249782A (en) Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof
TW201302674A (zh) 支鏈３－苯基丙酸衍生物及其用途
WO2014068095A1 (fr) Imidazo[1,2-a]pyridincarboxamides carboxy-substitués et leur utilistaion comme stimulants de la guanylate cyclase soluble
CA2633701C (fr) Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires
US8324222B2 (en) Cyclically substituted furopyrimidine derivatives and use thereof
EP2205604B1 (fr) Dérivés de l'acide { [5- ( phényl) - 6- phénylpyrrolo [2,1-f][2,1, 4]triazine-4-yl]amino} carboxylique et composés apparentés en tant qu'activateurs du récepteur de prostazykline (pgi2) ip pour le traitement de maladies cardiovasculaires
BR112020010837A2 (pt) processo para preparar ácido (3s)-3-(4-cloro-3-{[(2s,3r)- 2-(4-clorofenil)-4,4,4-trifluoro-3- metilbutanoil]amino}fenil)-3-ciclopropilpropanoico e sua forma cristalina para uso como composto farmaceuticamente ativo
CA2685134A1 (fr) Utilisation de derives de furopyrimidine a substitution cyclique dans le traitement de l'hypertonie arterielle pulmonaire
US20100261736A1 (en) Substituted bicyclic heteroaryl compounds for the treatment of cardiovascular disease
US20110166163A1 (en) Substituted furopyrimidines and use thereof
US20110054017A1 (en) Substituted furans and their use
CA2685128A1 (fr) Utilisation de derives de furopyrimidine a substitution acyclique dans le traitement de l'hypertonie arterielle pulmonaire
MX2008008017A (en) Novel, cyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases
DE102007054786A1 (de) Trisubstituierte Furopyrimidine und ihre Verwendung

Legal Events

Date Code Title Description
FZDE Dead